Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At Abide Therapeutics, we have the pipeline and the people to become the world leader in realizing the therapeutic value of serine hydrolases like the endocannabinoid modulator monoacylglycerol lipase, or MGLL. Our commitment is to develop novel medicines to transform the lives of patients with serious unmet medical needs. Serine hydrolases form a large enzyme family that plays key roles in human physiology and disease. Using ...
At Abide Therapeutics, we have the pipeline and the people to become the world leader in realizing the therapeutic value of serine hydrolases like the endocannabinoid modulator monoacylglycerol lipase, or MGLL. Our commitment is to develop novel medicines to transform the lives of patients with serious unmet medical needs. Serine hydrolases form a large enzyme family that plays key roles in human physiology and disease. Using our unique and proprietary serine hydrolase platform combined with our deep scientific and drug development expertise, we have advanced to the clinic a new class of drugs for neurological diseases.

List your booth number for exhibitions, ask us